|
Oct 2
|
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
|
|
Aug 29
|
Immix Biopharma Independent Director Acquires 2.6% More Stock
|
|
Aug 28
|
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
|
|
Jul 26
|
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
|
|
Jun 17
|
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
|
|
May 23
|
Immix Biopharma Insiders Placed Bullish Bets Worth US$625.7k
|
|
May 10
|
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
|
|
Apr 29
|
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
|
|
Apr 18
|
Immix Biopharma on Track to Dose NXC-201 Patients in United States
|
|
Apr 15
|
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
|
|
Mar 20
|
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
|
|
Mar 5
|
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
|
|
Jan 11
|
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
|
|
Jan 4
|
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
|
|
Dec 18
|
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
|
|
Nov 30
|
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
|
|
Nov 28
|
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'
|
|
Aug 23
|
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma
|
|
Apr 26
|
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
|